FDA’s Distributed Manufacturing Rule: What One Registration Means for CQV & Quality
July 30, 2026
At a Glance
One registration sounds like less work. It is actually more accountability — spread across every node of your network.
The RuleSingle registration for your entire distributed manufacturing network.The FDA's proposed July 2026 rule eliminates the need to register each site separately — but unifies compliance exposure across the entire hub-and-spoke system.
The ImplicationA quality failure at one spoke is a problem for every spoke.One registration means one compliance posture. Validation drift, data integrity gaps, or a deviation at any node now carries network-wide regulatory risk.
The FDA's proposed rule released in July 2026 marks a significant step toward modernizing drug establishment registration. Under the proposal, companies operating Distributed Manufacturing (DM) systems — a hub-and-spoke model that uses modular, mobile, or decentralized manufacturing units — would be able to register their entire manufacturing network under a single establishment registration rather than registering each manufacturing site separately.
On paper, this could be a massive administrative victory. It lowers registration costs, simplifies the reporting pipeline, and eliminates the legacy headache of maintaining separate FDA facility registrations for every individual spoke.
However, behind this administrative relief lies an important operational reality: one registration also means thinking about risk as a unified system, not as independent manufacturing sites.
If decentralized manufacturing units are not operating as a single, consistently controlled system, a compliance issue, validation drift, or data integrity problem at one spoke can create broader quality, operational, and regulatory challenges across the manufacturing network.
To leverage this proposed rule safely, life science companies must look past the administrative streamlining and focus on the real challenge: how do you ensure all manufacturing units operate in a unified, fully validated manner?
The Core Strategy: Unified Governance for Distributed Networks
Under the proposed rule, the FDA expects the central quality hub to maintain complete, real-time control over all decentralized spokes. Achieving this requires moving away from localized, site-specific validation and quality silos. To build an ironclad, unified network, organizations must focus on three core pillars.
01
Templated, Modular CQV
In a hub-and-spoke model, physical spoke units may be relocated, added, or scaled rapidly. Traditional, site-specific IQ and OQ approaches were designed for fixed facilities, not dynamic manufacturing networks. As manufacturing continues to evolve, validation strategies must become more scalable, risk-based, and lifecycle-focused to support distributed operations.
The unified approach: establish a master, templated qualification process. Instead of validating each physical unit in isolation, validate the critical operating envelope — HVAC tolerances, power parameters, utility connections — that any qualified spoke must meet.
Actionable StepStructure validation protocols so that any qualified spoke unit can plug and play into an approved facility envelope, relying on pre-validated parameters to instantly verify state of control.
02
Centralized Software & Data Integrity (CSA & CSV)
The FDA's proposed rule explicitly highlights the central quality hub's role in oversight. If your spokes rely on edge computing, local PLCs, or IoT devices to feed data back to your central eQMS, your digital infrastructure is the nervous system of your entire license.
The unified approach: transition from paper-based, localized CSV to a standardized Computer Software Assurance (CSA) framework. Focus high-intensity testing on the central data orchestrator, user access controls, and encryption pathways. Shifting to digital validation at this stage is a strategic financial decision that directly drives operational scalability and reduces long-term labor intensity.
Actionable StepDon't just validate normal operations. Execute and document validation testing for network latency and connection failure modes. What happens when a spoke loses connection to the hub mid-batch? The system must be proven to safely cache data, fail-safe, or halt production without corrupting the batch record.
03
Continuous Process Verification (CPV) Over Static Validation
Traditional validation approaches were designed to demonstrate control at a specific point in time. For a distributed network with multiple identical lines operating across different geographic locations, relying solely on localized, static validation creates the risk of undetected process drift. As manufacturing becomes more connected and data-driven, CQV is increasingly shifting from execution-focused activities toward lifecycle governance, where ongoing monitoring, trending, and risk management become essential.
The unified approach: implement centralized Continuous Process Verification. By pulling real-time data from all active spokes into a central analytical hub, quality teams can actively monitor Critical Process Parameters (CPPs) and Critical Quality Attributes (CQAs) across the entire network.
Actionable StepEstablish centralized statistical process control (SPC) thresholds. If Spoke A in Ohio begins to show minor thermal drift compared to Spoke B in Texas, your quality team must be alerted to intervene before a deviation occurs — not after.
Navigating the Dual-Edge of Streamlined Compliance
The FDA's proposed rule signals continued movement toward more agile, decentralized manufacturing models. However, simplified registration does not eliminate the operational challenges of managing a distributed manufacturing network. As manufacturing becomes more modular and interconnected, organizations will need the ability to govern, monitor, and validate every unit as part of one unified quality system.
Building a unified quality and validation infrastructure is not just about passing an audit. It is about ensuring every manufacturing unit operates within a consistent state of control and protecting the broader manufacturing network from localized failures.
As the regulatory landscape evolves, companies preparing for distributed, modular, or decentralized manufacturing will need scalable CQV strategies, digital validation frameworks, and centralized quality governance models designed for the future of manufacturing.
Simplified registration only delivers its promise if your quality infrastructure is genuinely unified — not locally compliant at each site but siloed across the network.
Partner With AVS Life Sciences
Build a CQV Strategy Your Entire Network Can Depend On
AVS Life Sciences partners with CQV and Quality specialists to design, assess, and implement CQV and quality strategies that enable consistent, compliant, and scalable manufacturing operations across distributed networks.
Frequently Asked Questions About FDA's Distributed Manufacturing Rule
The FDA's proposed rule, released in July 2026, would allow companies operating Distributed Manufacturing systems — a hub-and-spoke model using modular, mobile, or decentralized manufacturing units — to register their entire manufacturing network under a single establishment registration rather than registering each site separately.
One registration means one unified compliance posture. A quality issue, validation drift, or data integrity problem at any spoke in the network can create regulatory exposure across the entire registered system. Organizations must move away from localized, site-specific validation silos and toward centralized governance frameworks that treat every manufacturing unit as part of one validated system.
The three core pillars are: (1) Templated, modular CQV — establishing a master qualification process validated around a critical operating envelope rather than individual sites; (2) Centralized software and data integrity through a CSA framework focused on the central data orchestrator and network failure modes; and (3) Continuous Process Verification — pulling real-time data from all active spokes into a central analytical hub to monitor CPPs and CQAs across the network.
AVS Life Sciences designs all three capabilities — from templated qualification frameworks through centralized CPV programs — for hub-and-spoke manufacturing networks.
Distributed manufacturing networks rely on edge computing, local PLCs, and IoT devices feeding data to a central eQMS — making the digital infrastructure the nervous system of the entire license. A standardized CSA framework concentrates high-intensity testing on the central data orchestrator, user access controls, and encryption pathways, and requires documented validation of network failure modes that traditional CSV was never designed to address.
AVS Life Sciences partners with organizations to design, assess, and implement CQV and quality strategies that enable consistent, compliant, and scalable manufacturing operations — including templated qualification frameworks, CSA transitions, and centralized Continuous Process Verification programs designed for hub-and-spoke manufacturing networks.
